Middle East Unrest

Showing 643 articles
Business

Gilead Sciences Oncology Update After Positive Trodelvy Keytruda Trial Results

Gilead Sciences (NasdaqGS:GILD) reported positive Phase 3 ASCENT-04/KEYNOTE-D19 results for Trodelvy plus Keytruda in first-line metastatic triple-negative breast cancer. Full Phase 3 clinical data were published in a leading medical journal, highlighting efficacy and safety outcomes for the combination regimen. Following these results, Gilead submitted supplemental regulatory filings to the FDA and EMA seeking expanded use of Trodelvy in this setting. For you as an investor, this update...

Business

TSMC's Global Dominance and AI Boom Fuel Bullish Investment Thesis

Taiwan Semiconductor Manufacturing Company (TSMC) continues to solidify its position as the indispensable engine of the global tech industry. Driven by insatiable AI demand and strategic global expansion, the chipmaking titan's financial performance and long-term outlook are drawing intense investor scrutiny and bullish projections.

Business

Simon Property Group Caps Strong Year with Strategic Acquisitions and Record Returns, Outlines Aggressive 2026 Growth Plan

Simon Property Group reported robust fourth-quarter and full-year 2025 results, highlighted by record funds from operations, $2 billion in strategic acquisitions, and a significant return of capital to shareholders. The retail REIT giant provided optimistic 2026 guidance, banking on a strong development pipeline and resilient tenant demand despite acknowledging tariff-related headwinds.